Quantitative Scientist Discusses Considerations for HTAs Using RWD

Dr. Philani Brian Mpofu discusses important considerations for health technology assessments (HTAs) using real world data (RWD) to understand drug efficacy. He highlights the intricacies of RWD studies using a fictional drug, vidumab, manufactured by the fictional company Eland Pharma.

“After executing an observational study-design that was deliberate in recognizing and minimizing errors due to chance, selection bias, confounding and measurement error, Eland Pharma was able to show that there was evidence that their drug, vidumab, was likely more effective at treating melanoma than the current standard of care, luzumab.” Read more here.

(Source: Philani Brian Mpofu, Flatiron Health, 7/27/21)